New combo therapy aims to fix TSH suppression in thyroid cancer
NCT ID NCT07239674
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether combining desiccated thyroid extract (DTE) with standard levothyroxine can help intermediate-to-high risk thyroid cancer patients reach their TSH suppression targets faster and more safely after surgery. Many patients on levothyroxine alone struggle to achieve the right TSH levels, risking recurrence or side effects like heart problems and bone loss. The study will enroll 646 participants across China to compare the combination therapy against levothyroxine alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Desiccated thyroid extract (DTE) combined with levothyroxine (L-T4)
- What this could lead to
- If it works, this combination could help more thyroid cancer patients reach their target TSH levels faster and with fewer side effects than current standard therapy.
- What could go wrong
- This trial hasn't started yet, and even if successful, the benefit may be modest. The combination may also cause over-suppression or other hormone imbalances.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERMEDIATE-TO-HIGH RISK DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.